Presentation is loading. Please wait.

Presentation is loading. Please wait.

From: Systemic Treatment With Glutathione PEGylated Liposomal Methylprednisolone (2B3-201) Improves Therapeutic Efficacy in a Model of Ocular Inflammation.

Similar presentations


Presentation on theme: "From: Systemic Treatment With Glutathione PEGylated Liposomal Methylprednisolone (2B3-201) Improves Therapeutic Efficacy in a Model of Ocular Inflammation."— Presentation transcript:

1 From: Systemic Treatment With Glutathione PEGylated Liposomal Methylprednisolone (2B3-201) Improves Therapeutic Efficacy in a Model of Ocular Inflammation Invest. Ophthalmol. Vis. Sci ;55(4): doi: /iovs Figure Legend: Effect of intravenous dosing of 2B3-201 on EAU. (A) Incidence of clinical EAU in rats. (B) Clinical signs of uveitis in rats treated with vehicle (0.9% sodium chloride, in black), rats receiving one dose of 2B3-201 at day 10 (in red), rats treated with two doses of free MPhs (in green), or rats treated with 2B3-201 at days 14 and 18 (in blue) upon disease induction. Data represent the mean clinical scores ± SEM of 24 eyes per group. (C) Total disease burden integrated over time per individual animal (which is the cumulative EAU score per animal). *P < 0.05, **P < 0.01 by Mann-Whitney U test. Date of download: 10/27/2017 The Association for Research in Vision and Ophthalmology Copyright © All rights reserved.


Download ppt "From: Systemic Treatment With Glutathione PEGylated Liposomal Methylprednisolone (2B3-201) Improves Therapeutic Efficacy in a Model of Ocular Inflammation."

Similar presentations


Ads by Google